Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Artificial intelligence as the missing integrator in heart failure care — from remote monitoring to personalized therapy
0
Zitationen
24
Autoren
2026
Jahr
Abstract
Heart failure (HF) remains a leading cause of morbidity, mortality, and healthcare utilization worldwide, despite the availability of effective evidence-based therapies. The principal challenge is no longer the absence of treatment options but the limited capacity of traditional care models to deliver guidelinedirected medical therapy (GDMT) consistently and at scale. The COVID-19 pandemic exposed the fragility of hospital-centered HF care, highlighting the need for more resilient, patient-centered management strategies. Remote monitoring (RM) has been proposed as a solution, yet its clinical impact has been inconsistent due to fragmented data streams, declining patient adherence, and heavy reliance on continuous human oversight. Artificial intelligence (AI) offers an opportunity to address these limitations by integrating multidimensional clinical data, enabling earlier detection of deterioration, supporting adherence, and prioritizing clinically meaningful interventions. Emerging evidence suggests that AI-assisted workflows can accelerate GDMT optimization and improve surrogate and clinical outcomes when implemented within supervised care pathways. This has led to the concept of next-generation remote monitoring (NGRM), in which AI analyzes longitudinal physiological and behavioral signals to generate context-aware alerts and actionable recommendations while reducing clinical workload. Successful implementation, however, requires rigorous validation, clear governance, integration with clinical workflows, and safeguards for safety, equity, and accountability. When embedded within structured HF care pathways, AI-enabled monitoring may help bridge the persistent gap between evidence and real-world implementation.
Ähnliche Arbeiten
Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC.
2021 · 19.543 Zit.
2013 ACCF/AHA Guideline for the Management of Heart Failure
2013 · 12.599 Zit.
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
2021 · 12.368 Zit.
Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?
2016 · 11.735 Zit.
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
2002 · 11.655 Zit.
Autoren
- Jacek Kubica
- Tomasz Topoliński
- Robert Gajda
- Przemysław Musz
- Aldona Kubica
- Ł Szarpak
- Krzysztof Nowicki
- Marcin Ziółkowski
- Sebastian Meszyński
- Sławomir Grzelak
- Oleksandr Sokolov
- Jakub Ratajczak
- Julia M. Umińska
- Piotr Niezgoda
- Klaudyna Grzelakowska
- Przemysła Podhajski
- Karolina Obońska
- Ewa Laskowska
- Ryszard Piotrowicz
- Agnieszka Tycińska
- Giuśeppe Specchia
- Stefan Frantz
- Stefan Störk
- Eliano P. Navarese
Institutionen
- Nicolaus Copernicus University(PL)
- National Veterinary Research Institute(PL)
- John Paul II Catholic University of Lublin(PL)
- Baylor College of Medicine(US)
- Bydgoszcz University of Science and Technology(PL)
- AGH University of Krakow(PL)
- Nicolaus Copernicus Astronomical Center(PL)
- Institute of Cardiology(PL)
- Cardinal Stefan Wyszynski University in Warsaw(PL)
- Medical University of Białystok(PL)
- University of Pavia(IT)
- Istituto Universitario di Studi Superiori di Pavia(IT)
- University of Würzburg(DE)
- Universitätsklinikum Würzburg(DE)